Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Gyre Therapeutics's share price for the quarter that ended in Dec. 2023 was $25.69. Gyre Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 76.6 Mil. Therefore, Gyre Therapeutics's market cap for the quarter that ended in Dec. 2023 was $1,967.7 Mil.
Gyre Therapeutics's quarterly market cap
stayed the same
from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($0.0 Mil) but then
increased
from Dec. 2022 ($0.0 Mil) to Dec. 2023 ($1,967.7 Mil).
Gyre Therapeutics's annual market cap
stayed the same
from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($0.0 Mil) but then
increased
from Dec. 2022 ($0.0 Mil) to Dec. 2023 ($1,967.7 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Gyre Therapeutics's Enterprise Value for Today is $1,310.7 Mil.
Gyre Therapeutics Market Cap Historical Data
The historical data trend for Gyre Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Gyre Therapeutics Market Cap Chart
Gyre Therapeutics Annual Data
Trend
Dec21
Dec22
Dec23
Market Cap
-
-
1,967.74
Gyre Therapeutics Semi-Annual Data
Dec21
Dec22
Dec23
Market Cap
-
-
1,967.74
Competitive Comparison of Gyre Therapeutics's Market Cap
For the Biotechnology subindustry, Gyre Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's Market Cap falls into.
Gyre Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Gyre Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (NAS:GYRE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Gyre Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Gyre Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Gyre Therapeutics (Gyre Therapeutics) Business Description
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GYRE has been successfully added to your